Hepatocellular carcinoma and other liver lesions

Medical Clinics of North America

Volumn 98, Issue 1, 2014, Pages 103-118

  Salgia, Reena ^a   Singal, Amit G ^b,c  

^a HENRY FORD HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Diagnosis; Liver cancer; Liver mass; Treatment

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AFLATOXIN; AXITINIB; BAVITUXIMAB; BEVACIZUMAB; CAPECITABINE; DASATINIB; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; FOLINIC ACID; G 202; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; GOLVATINIB; INC 280; NINTEDANIB; OPB 31121; OXALIPLATIN; PALBOCICLIB; PASIREOTIDE; PRAVASTATIN; R 05137382; TEMOZOLOMIDE; TEMSIROLIMUS; TH 302; TIVOZANIB; TS 1; UFT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB; VT 122;

BILE DUCT CARCINOMA; CANCER EPIDEMIOLOGY; CANCER PROGNOSIS; CANCER STAGING; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIFFERENTIAL DIAGNOSIS; DNA SYNTHESIS; GENETIC RISK; HEPATITIS B; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; LIVER CYST; LIVER FUNCTION; LIVER HEMANGIOMA; LIVER TUMOR; MEDICAL DECISION MAKING; MEDICAL SOCIETY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SURVIVAL RATE; TUMOR VOLUME;

DIAGNOSIS; LIVER CANCER; LIVER MASS; TREATMENT;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; DISEASE MANAGEMENT; HEPATECTOMY; HEPATITIS B, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MAGNETIC RESONANCE IMAGING; NEOPLASM STAGING; PARANEOPLASTIC SYNDROMES; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84888018764     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2013.09.003     Document Type: Review

References (92)

1. Ferlay J., Shin H.R., Bray F., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. El-Serag H.B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012, 142:1264-1273.e1.
3. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
4. Altekruse S.F., McGlynn K.A., Reichman M.E. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. JClin Oncol 2009, 27:1485-1491.
5. Llovet J.M., Bustamante J., Castells A., et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999, 29:62-67.
6. Altekruse S.F., McGlynn K.A., Dickie L.A., et al. Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008. Hepatology 2012, 55:476-482.
7. Padhya K.T., Marrero J.A., Singal A.G. Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol 2013, 29:285-292.
8. Bruix J., Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2010, 53:1-35.
9. Yang J.D., Kim W.R., Coelho R., et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011, 9:64-70.
10. Collier J., Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998, 27:273-278.
11. Lok A.S., Seeff L.B., Morgan T.R., et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009, 136:138-148.
12. Singal A.G., Volk M.L., Jensen D., et al. Asustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010, 8:280-288. 288.e1.
13. Beasley R. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988, 61:1942-1956.
14. El-Serag H.B., Tran T., Everhart J.E. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004, 126:460-468.
15. Marrero J.A., Fontana R.J., Fu S., et al. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. JHepatol 2005, 42:218-224.
16. Lee E., Edward S., Singal A.G., et al. Improving screening for hepatocellular carcinoma by incorporating data on levels of alpha-fetoprotein, over time. Clin Gastroenterol Hepatol 2013, 11:437-440.
17. Singal A.G., Waljee A., Mukherjee A., et al. Machine learning algorithms outperform conventional regression models in identifying risk factors for hepatocellular carcinoma in patients with cirrhosis. Gastroenterology 2012, 142:S984.
18. Velazquez R.F., Rodriguez M., Navascues C.A., et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003, 37:520-527.
19. Bruix J., Sherman M., Llovet J.M., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. JHepatol 2001, 35:421-430.
20. Zhang B.H., Yang B.H., Tang Z.Y. Randomized controlled trial of screening for hepatocellular carcinoma. JCancer Res Clin Oncol 2004, 130:417-422.
21. El-Serag H.B., Kramer J.R., Chen G.J., et al. Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. Gut 2011, 60:992-997.
22. Trevisani F., De N.S., Rapaccini G., et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002, 97:734-744.
23. Wong G.L., Wong V.W., Tan G.M., et al. Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. Liver Int 2008, 28:79-87.
24. Davila J.A., Henderson L., Kramer J.R., et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med 2011, 154:85-93.
25. Davila J.A., Morgan R.O., Richardson P.A., et al. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology 2010, 52:132-141.
26. Singal A.G., Yopp A., S Skinner C., et al. Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. JGen Intern Med 2012, 27:861-867.
27. Singal A., Volk M.L., Waljee A., et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009, 30:37-47.
28. Singal A.G., Conjeevaram H.S., Volk M.L., et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev 2012, 21:793-799.
29. Singal A.G., Nehra M., Adams-Huet B., et al. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail?. Am J Gastroenterol 2013, 108:425-432.
30. Marrero J.A., Feng Z., Wang Y., et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009, 137:110-118.
31. Iwasaki M., Furuse J., Yoshino M., et al. Sonographic appearances of small hepatic nodules without tumor stain on contrast-enhanced computed tomography and angiography. JClin Ultrasound 1998, 26:303-307.
32. Jeong Y.Y., Mitchell D.G., Kamishima T. Small (<20 mm) enhancing hepatic nodules seen on arterial phase MR imaging of the cirrhotic liver: clinical implications. AJR Am J Roentgenol 2002, 178:1327-1334.
33. Forner A., Vilana R., Ayuso C., et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008, 47:97-104.
34. Marrero J.A., Fontana R.J., Barrat A., et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005, 41:707-716.
35. Trevisani F., D'Intino P.E., Caraceni P., et al. Etiologic factors and clinical presentation of hepatocellular carcinoma. Differences between cirrhotic and noncirrhotic Italian patients. Cancer 1995, 75:2220-2232.
36. Yuen M.F., Cheng C.C., Lauder I.J., et al. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000, 31:330-335.
37. Singal A.G., Yopp A.C., Gupta S., et al. Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res (Phila) 2012, 5:1124-1130.
38. Katyal S., Oliver J.H., Peterson M.S., et al. Extrahepatic metastases of hepatocellular carcinoma. Radiology 2000, 216:698-703.
39. Lee Y.T., Geer D.A. Primary liver cancer: pattern of metastasis. JSurg Oncol 1987, 36:26-31.
40. Luo J.C., Hwang S.J., Wu J.C., et al. Clinical characteristics and prognosis of hepatocellular carcinoma patients with paraneoplastic syndromes. Hepatogastroenterology 2002, 49:1315-1319.
41. Singal A.G., Rakoski M.O., Salgia R., et al. The clinical presentation and prognostic factors for intrahepatic and extrahepatic cholangiocarcinoma in a tertiary care centre. Aliment Pharmacol Ther 2010, 31:625-633.
42. Darwish Murad S., Kim W.R., Harnois D.M., et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012, 143:88-98.e3. [quiz: e14].
43. Salgia R.J., Singal A.G., Fu S., et al. Improved post-transplant survival in the United States for patients with cholangiocarcinoma after 2000. Dig Dis Sci 2013, [Epub ahead of print].
44. Glimelius B., Hoffman K., Sjoden P.O., et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996, 7:593-600.
45. Bilgili Y., Firat Z., Pamuklar E., et al. Focal liver lesions evaluated by MR imaging. Diagn Interv Radiol 2006, 12:129-135.
46. Hsee L.C., McCall J.L., Koea J.B. Focal nodular hyperplasia: what are the indications for resection?. HPB (Oxford) 2005, 7:298-302.
47. van Aalten S.M., de Man R.A., IJzermans J.N., et al. Systematic review of haemorrhage and rupture of hepatocellular adenomas. Br J Surg 2012, 99:911-916.
48. Stoot J.H., Coelen R.J., De Jong M.C., et al. Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. HPB (Oxford) 2010, 12:509-522.
49. Ault G.T., Wren S.M., Ralls P.W., et al. Selective management of hepatic adenomas. Am Surg 1996, 62:825-829.
50. Bioulac-Sage P., Balabaud C., Zucman-Rossi J. Subtype classification of hepatocellular adenoma. Dig Surg 2010, 27:39-45.
51. Nault J.C., Bioulac-Sage P., Zucman-Rossi J. Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology 2013, 144:888-902.
52. Martin D.R., Semelka R.C. Imaging of benign and malignant focal liver lesions. Magn Reson Imaging Clin N Am 2001, 9:785-802. vi-vii.
53. Semelka R.C., Hussain S.M., Marcos H.B., et al. Biliary hamartomas: solitary and multiple lesions shown on current MR techniques including gadolinium enhancement. JMagn Reson Imaging 1999, 10:196-201.
54. Heneghan H.M., Healy N.A., Martin S.T., et al. Modern management of pyogenic hepatic abscess: a case series and review of the literature. BMC Res Notes 2011, 4:80.
55. Karavias D., Panagopoulos C., Vagianos C., et al. Infected echinococcal cyst. A common cause of pyogenic hepatic abscess. Ups J Med Sci 1988, 93:289-296.
56. Farges O., Malassagne B., Flejou J.F., et al. Risk of major liver resection in patients with underlying chronic liver disease: a reappraisal. Ann Surg 1999, 229:210-215.
57. de Graaf W., van Lienden K.P., van den Esschert J.W., et al. Increase in future remnant liver function after preoperative portal vein embolization. Br J Surg 2011, 98:825-834.
58. Llovet J.M., Fuster J., Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999, 30:1434-1440.
59. Poon R.T. Optimal initial treatment for early hepatocellular carcinoma in patients with preserved liver function: transplantation or resection?. Ann Surg Oncol 2007, 14:541-547.
60. Poon R.T., Fan S.T., Ng I.O., et al. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000, 89:500-507.
61. Portolani N., Coniglio A., Ghidoni S., et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg 2006, 243:229-235.
62. Zhou W.P., Lai E.C., Li A.J., et al. Aprospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg 2009, 249:195-202.
63. Onaca N., Davis G.L., Jennings L.W., et al. Improved results of transplantation for hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl 2009, 15:574-580.
64. Lesurtel M., Mullhaupt B., Pestalozzi B.C., et al. Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am J Transplant 2006, 6:2644-2650.
65. Thuluvath P.J., Guidinger M.K., Fung J.J., et al. Liver transplantation in the United States, 1999-2008. Am J Transplant 2010, 10:1003-1019.
66. Yao F.Y., Ferrell L., Bass N.M., et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001, 33:1394-1403.
67. Mazzaferro V., Llovet J.M., Miceli R., et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009, 10:35-43.
68. Volk M.L., Vijan S., Marrero J.A. Anovel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant 2008, 8:839-846.
69. Mazzaferro V., Bhoori S., Sposito C., et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl 2011, 17(Suppl 2):S44-S57.
70. Yao F.Y., Kerlan R.K., Hirose R., et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008, 48:819-827.
71. Brunello F., Veltri A., Carucci P., et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand J Gastroenterol 2008, 43:727-735.
72. Lin S.M., Lin C.J., Lin C.C., et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or= 4 cm. Gastroenterology 2004, 127:1714-1723.
73. Lin S.M., Lin C.J., Lin C.C., et al. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005, 54:1151-1156.
74. Livraghi T., Goldberg S.N., Lazzaroni S., et al. Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology 2000, 214:761-768.
75. Shiina S., Teratani T., Obi S., et al. Arandomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005, 129:122-130.
76. Cho Y.K., Kim J.K., Kim M.Y., et al. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009, 49:453-459.
77. Chen M.S., Li J.Q., Zheng Y., et al. Aprospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006, 243:321-328.
78. Huang G.T., Lee P.H., Tsang Y.M., et al. Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study. Ann Surg 2005, 242:36-42.
79. Lu M.D., Kuang M., Liang L.J., et al. Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: a randomized clinical trial. Zhonghua Yi Xue Za Zhi 2006, 86:801-805.
80. Molinari M., Helton S. Hepatic resection versus radiofrequency ablation for hepatocellular carcinoma in cirrhotic individuals not candidates for liver transplantation: a Markov model decision analysis. Am J Surg 2009, 198:396-406.
81. Llovet J.M., Real M.I., Montana X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002, 359:1734-1739.
82. Pomoni M., Malagari K., Moschouris H., et al. Post embolization syndrome in doxorubicin eluting chemoembolization with DC bead. Hepatogastroenterology 2012, 59:820-825.
83. Lammer J., Malagari K., Vogl T., et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010, 33:41-52.
84. Burrel M., Reig M., Forner A., et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting Beads. Implications for clinical practice and trial design. JHepatol 2012, 56:1330-1335.
85. Salem R., Lewandowski R.J., Mulcahy M.F., et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010, 138:52-64.
86. Salem R., Lewandowski R.J., Kulik L., et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011, 140:497-507.e2.
87. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. NEngl J Med 2008, 359:378-390.
88. Lencioni R., Kudo M., Ye S.L., et al. First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib) non-interventional study. Int J Clin Pract 2012, 66:675-683.
89. Worns M.A., Weinmann A., Pfingst K., et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. JClin Gastroenterol 2009, 43:489-495.
90. Cheng A., Kang Y.K., Lin D., et al. Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). JClin Oncol 2011, 29S. [abstract 4000].
91. Finn R.S., Kang Y.K., Mulcahy M., et al. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012, 18:2090-2098.
92. Park J.W., Finn R.S., Kim J.S., et al. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2011, 17:1973-1983.